Description: Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).
Home Page: www.helixbiopharma.com
HBP Technical Analysis
401 Bay Street
Toronto,
ON
M5H 2Y4
Canada
Phone:
905 841 2300
Officers
| Name | Title |
|---|---|
| Mr. Hatem Kawar M.B.A., MBA, P.Eng, P.Eng. | Chief Financial Officer |
| Dr. Gabrielle M. Siegers M.A., Ph.D. | Head of R&D |
| Ms. Namrata Malhotra | Corp. Sec. |
Exchange: TO
Country: CA
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 133.1191 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 7 |